Predicting BCG Response
Trial Summary
What is the purpose of this trial?
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possesses the potential to accurately identify patients who will respond favorably to intravesical BCG is desperately needed.
Research Team
Charles Rosser, MD
Principal Investigator
Nonagen Bioscience Corporation
Hideki Furuya, PhD
Principal Investigator
Cedars-Sinai Medical Center
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intravesical BCG treatment
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Intravesical BCG
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cedars-Sinai Medical Center
Lead Sponsor
University of California, Los Angeles
Collaborator
National Cancer Institute (NCI)
Collaborator
Nonagen Bioscience Corporation
Industry Sponsor
University of California, San Francisco
Collaborator
University of Rochester
Collaborator
Kyoto University
Collaborator